desmopressin

GPTKB entity

Statements (41)
Predicate Object
gptkbp:instanceOf gptkb:drug
gptkbp:approvalYear 1978
gptkbp:ATCCode gptkb:H01BA02
gptkbp:brand gptkb:Minirin
gptkb:DDAVP
gptkb:Stimate
gptkbp:CASNumber 16679-58-6
gptkbp:chemicalFormula C46H64N14O12S2
gptkbp:contraindication hyponatremia
polydipsia
moderate to severe renal impairment
gptkbp:developedBy gptkb:vasopressin
gptkbp:discoveredBy gptkb:Novo_Nordisk
gptkbp:eliminationHalfLife 2–3 hours
gptkbp:excretion renal
https://www.w3.org/2000/01/rdf-schema#label desmopressin
gptkbp:isPeptide true
gptkbp:IUPACName (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(1-carbamoylethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
gptkbp:legalStatus prescription only
gptkbp:mechanismOfAction vasopressin receptor agonist
gptkbp:metabolism hepatic
gptkbp:molecularWeight 1069.22 g/mol
gptkbp:pregnancyCategory B (US)
B2 (Australia)
gptkbp:proteinBinding 40–50%
gptkbp:routeOfAdministration oral
intravenous
intranasal
sublingual
gptkbp:sideEffect nausea
abdominal pain
headache
hyponatremia
gptkbp:UNII Q528IWT3HI
gptkbp:usedFor gptkb:von_Willebrand_disease
gptkb:hemophilia_A
gptkb:diabetes_insipidus
bedwetting
gptkbp:bfsParent gptkb:von_Willebrand's_disease
gptkb:Imodium
gptkbp:bfsLayer 5